

# FRAU PD. DR. MED. PETRA FRANKE

PUBLIKATIONEN

## Publikationen

### ZEITSCHRIFTEN

1991

Leboyer M, Maier W, Teherani M, Lichtermann D, D'Amato T, **FRANKE P**, Lepine JP, Minges J, McGuffin P (1991) The reliability of the SADS-LA in a family study setting. *Eur. Arch. Psych. Clin. Neurosci.*, 241(3): 165-169.

1992

**FRANKE P**, Maier W, Hain Ch, Klingler Th (1992) Wisconsin Card Sorting Test: an indicator of vulnerability to schizophrenia? *Schizophrenia Research* 6: 243-249

Maier W, **FRANKE P**, Hain Ch, Kopp B, Rist F (1992) Neuropsychological indicators of the vulnerability to schizophrenia. *Prog Neuro-Psychopharmacol & Biol Psychiatry* 16:703-715

1993

**FRANKE P**, Maier W, Hardt J, Hain Ch (1993) Cognitive functioning and anhedonia in subjects at risk for schizophrenia. *Schizophrenia Research* 10: 77-84

**FRANKE P**, Maier W, Hardt J, Frieboes R, Lichtermann D, Hain Ch (1993) Assessment of frontal lobe functioning in schizophrenia and unipolar major depression. *Psychopathology* 26:76-84

Hain C, Maier W, Klingler T, **FRANKE P** (1993) Positive/negative symptomatology and experimental measures of attention in schizophrenic patients. *Psychopathology*, 26: 62-68

Maier W, Lichtermann D, Minges J, Oehrlein A, **FRANKE P** (1993) A controlled family study in panic disorder. *Journal of Psychiatric Research* 27:79-87

Maier W, Lichtermann D, Minges J, **FRANKE P**, Heun R, Hallmayer J (1993) Concordance for gender in sib pairs affected with schizophrenia and related disorders. *Schizophrenia Research*, 9: 71-76

1994

**FRANKE P**, Maier W, Hardt J, Hain Ch, Cornblatt BA (1994) Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings and controls. *Psychiatry Research* 54: 259-272

Maier W, Minges J, Lichtermann D, Heun R, **FRANKE P** (1994) Personality variations in healthy relatives of schizophrenics. *Schizophrenia Research*, 12: 81-88

Maier W, **FRANKE P**, Kopp B, Hain Ch, Rist F (1994) Reaction time paradigms in subjects at risk for schizophrenia. *Schizophrenia Research*, 13(1): 35-43

## 1995

Hain C, Maier W, Hoechst-Janneck S, **FRANKE P** (1995) Subclinical thought disorder in first-degree relatives of schizophrenic patients. Results from a matched-pairs study with the Thought Disorder Index. *Acta Psychiatr Scand*, 92(4): 305-309

Maier W, Minges J, Lichtermann D, **FRANKE P**, Gänsicke M (1995) Personality patterns in subjects at risk for affective disorders. *Psychopathology*, 28: 59-72

## 1996

**FRANKE P**, Maier W, Hautzinger M, Weiffenbach O, Gänsicke M, Iwers B, Poustka F, Schwab SG, Froster U (1996) Fragile-X Carrier Females: Evidence for a distinct psychopathological phenotype ? *Am J Med Genet* 64:334-339

Barbe B, **FRANKE P**, Maier W, Leboyer M, (1996) Fragile X syndrome I An overview on ist genetic mechanism. *European Psychiatry* 11:227-232

**FRANKE P**, Barbe B, Leboyer M, Maier W (1996) Fragile X syndrome II Cognitive and behavioral correlates of mutations of the FMR-1 gene. *European Psychiatry* 11:233- 243

Maier W, Schwab SG, **FRANKE P**; Gänsicke, M, Rietschel M (1996) Recent progress in genetics of schizophrenia. *Neurology, Psychiatry and Brain Research*, 4: 117-128

## 1997

Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E, **FRANKE P**, Nöthen MM, Maier W, Bellodi L, Lesch KP (1997) Functional promotor polymorphism of the human serotonin transporter: lack of association with panic disorder. *Psychiatric Genetics*, 7: 45-47

Steinlein OK, Deckert J, Nöthen NN, **FRANKE P**, Maier W, Beckmann H, Propping P (1997) Neuronal nicotinic acetylcholine receptor a4 subunit (CHRNA4) and panic disorder: an association study. *Am J Med Genet (Neuropsychiatric Genetics)*, 74: 199-201

Mann K, Maier W, **FRANKE P**, Röschke J, Gänsicke M (1997) Intra- and interhemispheric electroencephalogram coherence in siblings discordant for schizophrenia and healthy volunteers. *Biological Psychiatry*, 42: 655-663

## 1998

**FRANKE P**, Leboyer M, Gänsicke M, Weiffenbach O, Biancalana V, Cornillet-Lefebre P, Croquette MF, Froster U, Schwab SG, Poustka F, Hautzinger M, Maier W (1998)Genotype-phenotype relationship in female carriers of the pre- and full mutationof FMR-1. *Psychiatry Research*, 80 (2): 113-127

Deckert J, Nöthen NN, **FRANKE P**, Delmo C, Fritze J, Maier W, Beckmann H, Propping P (1998) Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. *Molecular Psychiatry*, 3: 81-85

**FRANKE P**, Maier W (1998) Genetik der substanzgebundenen Abhängigkeitserkrankungen.  
*Medizinische Genetik*, 3: 398-401

Maier W, **FRANKE P**, Hawellek B (1998) Special feature: family-genetic research strategies for personality disorders. *Journal of Personality Disorders*

### 1999

**FRANKE P**, Schwab SG, Knapp M, Gänsicke M, Delmo C, Zill P, Trixler M, Lichtermann D, Hallmayer J, Wildenauer DB, Maier W (1999) DAT1 Gene Polymorphism in alcoholism: a family based association study. *Biological Psychiatry*, 45: 652-654

**FRANKE P**, Nöthen MM, Wang T, Neit H; Knapp M, Lichtermann D, Weiffenbach O, Mayer P, Höllt V, Propping P, Maier W (1999) Human d-opioid receptor gene and susceptibility to heroin and alcohol dependence *Am J Med Genet (Neuropsychiatric Genetics)*, 88 (5): 462-464

**FRANKE P**, Leboyer M, Hardt J, Sohne E, Weiffenbach O, Biancalana V, Cornillet-Lefebre P, Delobel B, Froster U, Schwab SG, Poustka F, Hautzinger M, Maier W (1999) Neuropsychological profiles of FMR-1 premutation and full mutation females. *Psychiatry Research*, 87: 223-231

**FRANKE P**, Gänsicke M, Falkai P, Maier W (1999) Differential Memory Span – abnormal lateralization pattern in schizophrenics and their siblings ? *Int J Psychophysiology*, 34: 303-311

Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, Nothen MM; Maffai P, **FRANKE P**, Fritze J, Maier W, Propping P, Bellodi L, Lesch KP (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. *Hum Mol Genet*, 8(4): 621-624

### 2000

**FRANKE P**, Nöthen MM, Wang T, Knapp M, Lichtermann D, Neith H, Sander T, Propping P, Maier W (2000) DRD4 exon III polymorphism – susceptibility factor for heroin dependence ? Results of a case-control and a family based association approach. *Mol Psychiatry*, 5(1): 101-104

**FRANKE P**, Wang T, Nöthen MM, Knapp M, Neith H, Lichtermann D, Meyer zur Capellen K, Sander T, Propping P, Maier W (2000): Susceptibility for Alcoholism: DRD4 exon III polymorphism -a case-control and a family based association approach *Addiction Biology*, 5: 289-295

Hardt J, Gerbershagen HU, **FRANKE P** (2000) The symptom check-list, SCL-90-R: its use and characteristics in chronic pain patients. *European Journal of Pain*, 4: 137-148

**FRANKE P** (2000) Genetische Varianten des opioidergen Systems bei Suchterkrankungen. *Suchtmedizin*, 2(3): 127-133

Lichtermann D, **FRANKE P**, Maier W, Rao ML (2000) Pharmacogenomics and addiction to opiates. *Eur J Pharmacology*, 27;410(2-3):269-279

Lichtermann D, Hranilovic D, Trixler M, **FRANKE P**, Jernej B, Delmo CD, Knapp M, Schwab SG, Maier W, Wildenauer DB (2000) Support for allelic association of a polymorphic site in the promoter region of the serotonin transporter gene with risk for alcohol dependence. *Am J Psychiatry*, 157(12):2045-7

Sand PG, Godau C, Riederer P, Peters C, **FRANKE P**, Nothen MM, Stober G, Fritze J, Maier W, Propping P, Lesch KP, Riess O, Sander T, Beckmann H, Deckert J (2000) Exonic variants of the GABA(B) receptor gene and panic disorder. *Psychiatr Genetics*, 10(4):191-4

## 2001

**FRANKE P**, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W (2001) Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. *Am J Med Genet*, 8;105(1):114-9

Schneider F, Habel U, Wagner M, **FRANKE P**, Salloum JB, Shah NJ, Toni I, Sulzbach C, Honig K, Maier W, Gaebel W, Zilles K (2001) Subcortical correlates of craving in recently abstinent alcoholic patients. *Am J Psychiatry*, 158(7):1075-83

Wang T, **FRANKE P**, Neidt H, Cichon S, Knapp M, Lichtermann D, Maier W, Propping P, Nothen MM (2001) Association study of the low-activity allele of catechol-Omethyltransferase and alcoholism using a family-based approach. *Mol Psychiatry*, 6(1):109-11

Keppel S, Dilg C, **FRANKE P** (2001) Test-Retest und Interrater-Reliabilität des Semistrukturierten Interviews zur Genese von Alkohol- und Drogenabhängigkeit (SIGAD). *Suchtmedizin*, 3(4): 217-224

## 2002

Sand PG, Schlurmann K, Luckhaus C, Götz M, Stöber G, Lesch KP, Riederer P, **FRANKE P**, Maier W, Nöthen MM, Propping P, Fritze J, Deckert J (2002) Estrogen receptor 1 gene (ESR1) variants in panic disorder. *Am J Med Genet*, 114: 426-428.

Maier W, Lichtermann D, **FRANKE P**, Heun R, Falkai P, Rietschel M (2002) The dichotomy of schizophrenia and affective disorders in extended pedigrees. *Schizophr Res* 57: 259-266

## 2003

**FRANKE P**, Wendel B, Knapp M, Schwab SG, Neef D, Maier W, Wildenauer DB, Hoehe MR (2003): Introducing a new recruitment design for genetic association studies in opioid dependence. *Eur. Psychiatry*, 18(1), 18-22.

**FRANKE P**, Neef D, Weiffenbach O, Gänsicke M, Hautzinger M, Maier W (2003) Psychiatrische Komorbidität in Risikogruppen für Opiatabhängigkeit:: eine Untersuchung an opiatabhängigen und nicht-opiatabhängigen BtmG-Inhaftierten. *Fortschr Neurol Psychiat* 71(1): 37-44

**FRANKE P** (2003) Geschlechtsunterschiede in der genetischen Übertragung bei Suchterkrankungen – eine Übersicht basierend auf Familien-, Zwillings- und Adoptionsstudien. *J. Neurol. Neurochir. Psychiatr.* 4 (2) 21-28.

**FRANKE P** (2003) Genetik von Suchterkrankungen. *Psychoneuro* 29(4): 161-164.

Schumacher J, Otte AC, Becker T, Sun Y, Wienker TF, Wirth B, **FRANKE P**, Abou Jamra R, Propping P, Deckert J, Nothen MM, Cichon S. (2003) No evidence for DUP25 in patients with panic disorder using a quantitative real-time PCR approach. *Hum Genet*. 114(1):115-7.

## 2004

Domschke K, Freitag CM, Kuhlenbumer G, Schirmacher A, Sand P, Nyhuis P, Jacob C, Fritze J, **FRANKE P**, Rietschel M, Garritsen HS, Fimmers R, Nöthen MM, Lesch KP, Stegbauer F, Deckert J. (2004) Association of the functional V158M catechol- O-methyl-transferase polymorphism with panic disorder in women. *Int J Neuropsychopharmacol.* 7(2):183-8.

Hösing VG, Schirmacher A, Kuhlenbäumer G, Freitag C, Sand P, Schlesiger C, Jacob C, Fritze J, **FRANKE P**, Rietschel M, Garritsen H, Nöthen MM, Fimmers R, Stögbauer F, Deckert J (2004) Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. *J Neural Transm Suppl.*;[68]:147-56.

Rothe C, Koszycki D, Bradwejn J, King N, De Luca V, Shaikh S, **FRANKE P**, Garritsen H, Fritze J, Deckert J, Kennedy JL. (2004) Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. *Neurosci Lett.* 17;363(3):276-9.

Rothe C, Gutknecht L, Freitag C, Tauber R, MSSner R, **FRANKE P**, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Jacob C, Rietschel M, Nöthen MM, Garritsen H, Fimmers R, Deckert J, Lesch KP. (2004) Association of a functional 1019CG 5- HT1A receptor gene polymorphism with panic disorder with agoraphobia. *Int J Neuropsychopharmacol.* 7(2):189-92.

Xu K, Lichtermann D, Lipsky RH, **FRANKE P**, Liu X, Hu Y, Cao L, Schwab SG, Wildenauer DB, Bau CH, Ferro E, Astor W, Finch T, Terry J, Taubman J, Maier W, Goldman D. (2004) Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. *Arch Gen Psychiatry.* 61(6):597-606.

## 2005

Schwab SG, **FRANKE PE**, Hoefgen B, Guttenthaler V, Lichtermann D, Trixler M, Knapp M, Maier W, Wildenauer DB. (2005) Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. *Neuropsychopharmacology.* 30(12):2263-8.

Lee YJ, Hohoff C, Domschke K, Sand P, Kuhlenbäumer G, Schirmacher A, Freitag CM, Meyer J, Stöber G, **FRANKE P**, Nöthen MM, Fritze J, Fimmers R, Garritsen HS, Stögbauer F, Deckert J. (2005) Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. *Neurosci Lett.* 377(1):40-3.

Schumacher J, Abou Jamra R, Becker T, Klopp N, **FRANKE P**, Jacob C, Sand P, Fritze J, Ohlraun S, Schulze TG, Rietschel M, Illig T, Propping P, Cichon S, Deckert J, Nöthen MM (2005) Investigation of the DAOA/G30 locus in panic disorder. *Mol Psychiatry.* 10(5):428-9.

## 2006

Mossner R, Freitag CM, Gutknecht L, Reif A, Tauber R, **FRANKE P**, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Rietschel M, Garritsen H, Jacob C, Lesch KP, Deckert J. (2006) The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. *J Psychopharmacol.* 20(4):547-52.

Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J, **FRANKE P**, Bandelow B, Fimmers R, Flint J, Deckert J. [2006] Rgs 2 gene polymorphisms as modulators of anxiety in humans? *J Neural Transm.* 113(12):1921-5.

## 2007

Hardt J, **FRANKE P** [2007] Validity, reliability and objectivity of the family history method in psychiatry: A meta analysis. *Eur Psychiatry.* 22(1):49-58

## 2008

Mössner R, Schuhmacher A, Schulze-Rauschenbach S, Kühn KU, Rujescu D, Rietschel M, Zobel A, **FRANKE P**, Wölwer W, Gaebel W, Häfner H, Wagner M, Maier W (2008) Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. *Eur Neuropsychopharmacol.* 18(10):768-72

Racz I, Schürmann B, Karpushova A, Reuter M, Cichon S, Montag C, Fürst R, Schütz C, **FRANKE PE**, Strohmaier J, Wienker TF, Terenius L, Osby U, Gunnar A, Maier W, Bilkei-Gorzo A, Nöthen M, Zimmer A (2008) The opioid peptides enkephalin and beta-endorphin in alcohol dependence. *Biol Psychiat* 64(11):989-97

## 2009

Schuhmacher A, Mössner R, Quednow BB, Kühn KU, Wagner M, Cvetanovska G, Rujescu D, Zill P, Möller HJ, Rietschel M, **FRANKE P**, Wölwer W, Gaebel W, Maier W. (2009) Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. *Pharmacogenet Genomics.* 2009 Nov;19(11):843-51.

## 2011

Wölwer W, Frommann N, Jänner M, **FRANKE PE**, Scherbaum N, Lieb B, Falkai P, Wobrock T, Kuhlmann T, Radermacher M, Maier W, Schütz C, Ohmann C, Burtscheidt W, Gaebel W. (2011) The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. *Drug Alcohol Depend.* 2011 Nov 1;118(2-3):417-22.

Lennertz L, Rujescu D, Wagner M, Frommann I, Schulze-Rauschenbach S, Schuhmacher A, Landsberg MW, **FRANKE P**, Möller HJ, Wölwer W, Gaebel W, Häfner H, Maier W, Mössner R. (2011) Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in schizophrenia patients. *Neuropsychobiology.* 2011;63(3):131-6.

## 2012

Schuhmacher A, Becker T, Rujescu D, Quednow BB, Lennertz L, Wagner M, Benninghoff J, Rietschel M, Häfner H, **FRANKE P**, Wölwer W, Gaebel W, Maier W, Mössner R. (2012) Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. *J Psychiatr Res.* 2012 Aug;46(8):1073-80.

Lennertz L, Quednow BB, Schuhmacher A, Petrovsky N, Frommann I, Schulze-Rauschenbach S, Landsberg MW, Steinbrecher A, Höfels S, Pukrop R, Klosterkötter J, **FRANKE PE**, Wölwer W, Gaebel W, Häfner H, Maier W, Wagner M, Mössner R. (2012) The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response. *Int J Neuropsychopharmacol.* 2012 Oct;15(9):1205-15.

Lennertz L, Wagner M, Wölwer W, Schuhmacher A, Frommann I, Berning J, Schulze-Rauschenbach S, Landsberg MW, Steinbrecher A, Alexander M, **FRANKE PE**, Pukrop R, Ruhrmann S, Bechdolf A, Gaebel W, Klosterkötter J, Häfner H, Maier W, Mössner R. (2012) A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. *Eur Arch Psychiatry Clin Neurosci.* 2012 Mar;262(2):117-24.

## 2013

Lennertz L, **FRANKE PE**, Grabe HJ, Rampacher F, Schulze-Rauschenbach S, Guttenthaler V, Ruhrmann S, Pukrop R, Klosterkötter J, Falkai P, Maier W, Wagner M, Mössner R. (2013) The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive-compulsive disorder. *Int J Neuropsychopharmacol.* 2013 Oct;16(9):1951-8.

Preller KH, Wagner M, Sulzbach C, Hoenig K, Neubauer J, **FRANKE PE**, Petrovsky N, Frommann I, Rehme AK, Quednow BB. (2013) Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. *Eur Neuropsychopharmacol.* 2013 Oct;23(10):1270-9.

## 2014

Lennertz L, Wagner M, Grabe HJ, **FRANKE PE**, Guttenthaler V, Rampacher F, Schulze-Rauschenbach S, Vogeley A, Benninghoff J, Ruhrmann S, Pukrop R, Klosterkötter J, Falkai P, Maier W, Mössner R. (2014) 5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. *Eur Neuropsychopharmacol.* 2014 Jan;24(1):86-94.

## BUCHBEITRÄGE

### 2003

Maier W, **FRANKE P.** Biologie und Genetik der Sucht. In: Madea B, Brinkmann B (Hrsg.) Handbuch gerichtliche Medizin, Band II, Springer-Verlag, Heidelberg. 2003, S. 639-662.

### 2004

**FRANKE P.**, Schildberg F. Gruppentherapie zur Abstinenz- und Motivationsstärkung bei opiatabhängigen Patienten (GAMOA). Materialie 57, DGVT-Verlag, Tübingen, 2004.

### 2006

**FRANKE P.** Verhaltenstherapeutisch orientierte Gruppen während des qualifizierten Entzugs opiatabhängiger Patienten. In: Basdekis-Jozsa R, Krausz M (Hrsg.) Gruppentherapie in der Suchtbehandlung. Konzepte und praktisches Vorgehen. Klett- Cotta: leben-lernen 139, Stuttgart, 2006, S. 127-136

2008

**FRANKE P.**, Maier W. Genetische Epidemiologie. In: Holsboer F., Gründer G., Benkert O. (Hrsg.) Handbuch der Psychopharmakotherapie. Springer Medizin Verlag Heidelberg. 2008, S. 439-450.

2009

**FRANKE P.** & Schildberg F (2009: 2. Auflage) Gruppentherapie zur Abstinenz- und Motivationsstärkung bei opiatabhängigen Patienten. Ein verhaltens-therapeutisches Manual. Materialie 57. DGVT-Verlag, Tübingen, 97 Seiten plus Materialien.